Intensive COVID-19 testing associated with reduced mortality - an ecological analysis of 108 countries Chris Kenyon<sup>1,2</sup>\* <sup>1</sup>HIV/STI Unit, Institute of Tropical Medicine, Antwerp, Belgium; <sup>2</sup>Division of Infectious Diseases and HIV Medicine, University of Cape Town, Anzio Road, Observatory 7700, South Africa; \*Corresponding author. HIV/STI Unit, Institute of Tropical Medicine, Antwerp, 2000, Belgium. Tel: +32 3 2480796; Fax: +32 3 2480831; E-mail: ckenyon@itg.be 

**Keywords:** SARS CoV-2; COVID-19 mortality rate; testing intensity; epidemiology

Abstract

34

35 36

38

39

40

41

42

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

**Background** 

37 Intensive screening and testing for COVID-19 could facilitate early detection and

isolation of infected persons and thereby control the size of the epidemic. It could

also facilitate earlier and more targeted therapy. These factors could plausibly

reduce attributable mortality which was the hypothesis tested in this study.

#### Methods

Linear regression was used to assess the country-level association between COVID-

19 attributable mortality per 100 000 inhabitants (mortality/capita) and COVID-19

tests/capita (number of tests/100 000 inhabitants) controlling for the cumulative

number of COVID-19 infections/100 000 inhabitants (cases/capita), the age of the

epidemic (number of days between first case reported and 8 April), national health

expenditure per capita and WHO world region.

#### Results

The COVID-19 mortality rate varied between 0.3 and 3110 deaths/100 000

inhabitants (median 30, IQR 8-105). The intensity of testing per 100 000 also varied

considerably (median 21,970, IQR 2,735-89,095) as did the number of COVID-19

cases per 100 000 (median 1,600, IQR 340-4,760 cases/100 000). In the multivariate

model, the COVID-19 mortality rate was negatively associated with tests/capita

(Coef. -0.036, 95% CI -0.047- -0.025) and positively associated with cases/capita

(Coef. 0.093, 95% CI 0.819- 1.034).

Conclusions

60

61

- 62 The results are compatible with the hypothesis that intensive testing and isolation
- 63 could play a role in reducing COVID-10 mortality rates.

#### **Background**

It is important to understand the determinants of national variations in COVID-19-related mortality [1-4]. We aimed to evaluate if testing intensity plays a role. An obvious determinant of COVID-19 attributable mortality is the size of the national epidemic [2, 5, 6]. The measured extent of spread is however heavily dependent on the age of the epidemic and national testing policies [5, 6]. Because a majority of infections are pauci- or a-symptomatic a country that tests less intensively will tend to have a falsely low measured incidence and a correspondingly higher case fatality rate as fewer pauci-symptomatic infections are included in the denominator [5, 7]. Intensive screening and testing could however facilitate early detection and isolation of infected persons and thereby control the size of the epidemic [6, 8]. It could also facilitate earlier and more targeted therapy [8]. These factors could plausibly reduce attributable mortality [6].

We tested this hypothesis by using linear regression to assess the country-level association between COVID-19 attributable mortality per 100 000 inhabitants (mortality/capita) and COVID-19 tests/capita (number of tests/100 000 inhabitants) controlling for the cumulative number of COVID-19 infections/100 000 inhabitants (cases/capita), the age of the epidemic (number of days between first case reported and 8 April), national health expenditure per capita and WHO world region.

#### Methods

#### Dependent variable:

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Mortality/capita. The COVID-19 attributable mortality per 100 000 inhabitants. This data was obtained from the World of Meters data repository on 8 April 2020: https://www.worldometers.info/coronavirus/ Independent variables: Cases/capita. The cumulative number of cases of COVID-19 infection per 100 000 inhabitants on 8 April 2020 per country. This data was obtained from the World of Meters data repository on 8 April 2020: https://www.worldometers.info/coronavirus/ Tests/capita. Cumulative number of nucleic acid amplification SARS CoV-2 tests conducted per country per 100 000 inhabitants up till 8 April 2020. This data was obtained from the World of Meters data repository on 8 April 2020: https://www.worldometers.info/coronavirus/ Age of epidemic. The date the first case of COVID-19 was diagnosed in each country. This was measured in days after the first COVID-19 case was officially reported in China (10 January 2020). This data was obtained from the ECDC data repository on 8 April 2020: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases Health expenditure per capita. Current expenditures on health per capita in current US dollars for the year 2016. Estimates of current health expenditures include healthcare goods and services consumed during each year. This data was taken from the World Bank's Data Catalogue: https://datacatalog.worldbank.org/currenthealth-expenditure-capita-current-us

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

WHO regions. Countries were categorized according to WHO region: https://www.who.int/choice/demography/by country/en/ Data analysis A correlation matrix was performed to investigate the relationships between case fatality rate and the independent variables (Table 1). Linear regression was then used to analyze the association between the COVID-19 mortality rate/100 000 inhabitants and COVID-19 tests/capita (number of tests/100 000 inhabitants) controlling for the cumulative number of COVID-19 infections/100 000 inhabitants (cases/capita), the age of the epidemic (number of days between first case reported and 8 April), national health expenditure per capita and WHO world region. The most recent data available as of 8 April 2020 was used for all variables. Sensitivity analyses were conducted limiting the analysis to countries whose epidemics were older than 15 March 2020. A p-value of < 0.01 was considered statistically significant. The analyses were performed in STATA version 16 (Stata Corp., College Station, Tx). Results Complete data was available for 108 countries. The COVID-19 mortality rate varied between 0.3 and 3110 deaths/100 000 inhabitants (median 30, IQR 8-105; Table 3). The intensity of testing per 100 000 also varied considerably (median 21,970, IQR 2,735-89,095) as did the number of COVID-19 cases per 100 000 (median 1,600, IQR 340-4,760 cases/100 000)

Pearson's correlation revealed deaths/capita to be positively correlated with cases/capita (r=0.80, P<0.001), which was in turn positively correlated with tests/capita (r=0.55, P<0.001), and health care expenditure (r=0.51, P<0.001; Table 1). Tests/capita was positively correlated with health care expenditure (r=0.45, P<0.001).

In the multivariate model, the COVID-19 mortality rate was negatively associated with tests/capita (Coef. -0.036, 95% CI -0.047- -0.025) and positively associated with cases/capita (Coef. 0.093, 95% CI 0.819- 1.034; Table 2). Sensitivity analyses limited to countries with epidemics older than 15 March 2020 made little difference to the findings (Table 4).

#### Conclusion

Our analysis confirms the logical association between increased testing intensity and increased detection of cases/capita as well the association between cases/capita and deaths/capita. The key finding was that on multivariate analysis, testing intensity was negatively associated with mortality/capita. This is compatible with the theory that intensive testing is associated with reduced mortality via reducing the spread of SARS-CoV-2 and/or facilitating earlier more appropriate treatment of infected persons [6, 8]. Our study design does not allow us to exclude the possibility that this association is due to residual confounding. Possible confounders include other components of a successful national COVID-19 containment strategy such as contact tracing or social distancing [2, 5]. These may be associated with both increased testing intensity and reduced transmission/deaths. In addition, we did not

control for other variables such as national age structure and prevalence of comorbidities which may have influenced mortality [9].

These limitations notwithstanding, our analysis provides additional evidence to promote calls to intensify national COVID-19 testing to not only control the spread of this disease but also to reduce associated mortality.

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

**Authors' contributions** CK conceptualized the study, was responsible for the acquisition, analysis and interpretation of data and wrote the analysis up as a manuscript. **Funding** Nil **Conflict of interest** The author declares that he/she has no competing interests. **Ethical approval** The analysis involved a secondary analysis of public access ecological level data. As a result, no ethics approval was necessary. Informed consent Not applicable Acknowledgements Nil

Table 1. Correlation coefficients (r-values) for relations between COVID-19 mortality rate/100 000 inhabitants, cumulative number of cases of COVID-19/100 000, testing rate/100 000, age of the COVID-19 epidemic and health expenditure per capita (\* P<0.001)

	Mortality	Cumulative Cases	Testing Intensity	Age of Epidemic	Health Expenditure
Mortality Rate	1				
Cumulative Cases	0.80*	1			
Testing Intensity	0.17	0.55*	1		
Age of Epidemic	-0.14	-0.13	-0.16	1	
Health Expenditure	0.27	0.51*	0.45*	-0.43*	1

## Table 2. Country level, multivariate linear regression of factors associated

### with COVID-19 mortality rate per 100 000 inhabitants

	Coef. (95% Confidence Interval)	P-Value
N	108	
Tests/capita	-0.036 (-0.0050.002)	<0.001
Cases/capita	0.093 (0.082- 0.103)	<0.001
Age of Epidemic	-0.092 (-0.1720.011)	0.026
Health Expenditure	-0.0009 (-0.00160.0002)	0.011
Region		
Europe	Ref	
Africa	0.154 (-3.725-4.034)	0.937
Americas	0.047 (-2.849-2.944)	0.974
Eastern Mediterranean	0.986 (-2.720-4.692)	0.599
South East Asia	-2.072 (-7.047-2.903)	0.411
Western Pacific	0.094 (-4.461-4.651)	0.967

Table 3. COVID-19 mortality rate/100 000 inhabitants, cumulative number of cases of COVID-19/100 000 (Cases/capita), number tested for COVID-19/100 000 (Tests/capita), date first COVID-19 case reported (Age Epi.) and health expenditure (Health Exp – in US\$) in 108 countries.

Country	Mortality	Cases/capita	Tests/Capita	Age Epi.	Health Exp.
Albania	0.8	13.9	103.9	07-Mar-20	272
Algeria	0.4	3.3	7.7	24-Feb-20	260
Andorra	29.8	730	2165.3	01-Mar-20	3835
Antigua and Barbuda	2	19.4	40.8	12-Mar-20	623
Argentina	0.1	3.8	26.1	02-Mar-20	955
Armenia	0.3	29.7	184	29-Feb-20	359
Australia	0.2	23.6	1252.4	24-Jan-20	5002
Austria	3	143.2	1340.8	24-Feb-20	4688
Azerbaijan	0.08	8.1	525.7	27-Feb-20	268
Bahrain	0.3	48.2	3076.6	23-Feb-20	1099
Bangladesh	0.01	0.1	2.6	07-Mar-20	34
Barbados	1	21.9	193.8	16-Mar-20	1164
Belarus	0.1	11.3	486.8	27-Feb-20	318
Belgium	19.3	201.9	726.9	03-Feb-20	4149
Belize	0.3	2	67.4	22-Mar-20	304
Bolivia	0.1	1.8	5.1	09-Mar-20	213
Bosnia and	1	24.5	210.6	04-Mar-20	444
Herzegovina					
Brazil	0.3	6.7	25.8	24-Feb-20	1016
Brunei	0.2	30.9	2021.8	08-Mar-20	630
Bulgaria	0.3	8.5	228.8	06-Mar-20	612
Canada	1	48.9	922.3	24-Jan-20	4458
Chile	0.3	29	315.9	02-Mar-20	1191
Colombia	0.1	3.5	59.8	05-Mar-20	340
Costa Rica	0.04	9.5	108.5	04-Mar-20	889
Croatia	0.5	32.7	319.7	24-Feb-20	884
Cuba	0.1	3.5	62.3	10-Mar-20	971
Cyprus	0.7	43.6 47	1182.2	08-Mar-20 29-Feb-20	1634
Czechia	0.8		921.5		1321
Denmark		93	1008.6 41.9	26-Feb-20 29-Feb-20	5566 414
Dominican Republic  Ecuador	1.2	19.5 22.6	81.7	29-Feb-20 28-Feb-20	505
	0.09	1.4	24.4	13-Feb-20	131
Egypt Estonia	1.8	89.3	1870.5	26-Feb-20	1185
Ethiopia	0.002	0.05	2.2	12-Mar-20	28
Finland	0.002	44.9	658.8	28-Jan-20	4117
France	15.8	167.1	343.6	28-Jan-20 23-Jan-20	4263
Georgia	0.08	5.2	69.2	25-Jan-20 25-Feb-20	308
Georgia	0.08	5.2	69.2	25-160-20	308

Cormony	2.5	130.5	1096.2	26-Jan-20	4714
Germany		18.1	274.2	25-Feb-20	
Greece	0.8				1511
Guatemala	0.02	0.5	6.3	12-Mar-20	241
Guyana	0.6	4.2	16.8	11-Mar-20	192
Haiti	0.009	0.2	2.3	19-Mar-20	38
Hungary	0.6	9.3	266.5	03-Mar-20	943
Iceland	1.8	473.6	9068.9	27-Feb-20	5064
India	0.01	0.4	10.2	29-Jan-20	63
Indonesia	0.09	1.1	5.2	01-Mar-20	112
Iran	4.8	76.9	251.4	18-Feb-20	415
Iraq	0.2	3	70.6	21-Feb-20	153
Ireland 	4.3	115.6	860.4	28-Feb-20	4759
Israel	0.8	108.6	1355.7	20-Feb-20	2837
Italy	28.3	224.3	1249.5	29-Jan-20	2739
Jamaica	0.1	2.1	18.2	09-Mar-20	296
Japan 	0.07	3.4	43.7	14-Jan-20	4233
Jordan	0.06	3.5	166.6	01-Mar-20	224
Kazakhstan	0.04	3.8	302.4	12-Mar-20	262
Kenya	0.01	0.3	9.2	12-Mar-20	66
Kyrgyzstan	0.06	4.1	147.4	17-Mar-20	73
Latvia	0.1	30.6	1274.3	01-Mar-20	874
Lebanon	0.3	8.4	158.3	20-Feb-20	662
Lithuania	0.6	33.5	1106	27-Feb-20	988
Luxembourg	7	474.5	4105.9	28-Feb-20	6271
Malaysia	0.2	12.7	179.9	24-Jan-20	362
Mauritania	0.02	0.1	1.4	12-Mar-20	47
Mauritius	0.6	21.5	386.3	17-Mar-20	553
Mexico	0.1	2.2	19.7	27-Feb-20	462
Moldova	0.7	29.1	126.6	06-Mar-20	171
Montenegro	0.3	39.5	320.7	16-Mar-20	532
Morocco	0.2	3.4	15.2	01-Mar-20	171
Myanmar	0.006	0.04	2.3	22-Mar-20	62
Netherlands	13.1	119.9	505.3	26-Feb-20	4742
New Zealand	0.02	25.1	972.1	27-Feb-20	3745
Niger	0.05	1.1	17.3	18-Mar-20	23
Nigeria	0.003	0.1	2.4	27-Feb-20	79
North Macedonia	1.4	29.6	299	25-Feb-20	328
Norway	1.7	112.3	2100.9	25-Feb-20	7478
Pakistan	0.03	1.9	19.1	25-Feb-20	40
Panama	1.4	52.1	238.6	09-Mar-20	1041
Paraguay	0.07	1.7	28.6	06-Mar-20	327
Peru	0.3	9	65.4	05-Mar-20	316
Philippines	0.2	3.5	22.4	29-Jan-20	129
Poland	0.4	13.2	262.3	03-Mar-20	809

Portugal	3.7	128.9	1263	01-Mar-20	1801
Qatar	0.2	76.7	1451.5	28-Feb-20	1827
Romania	1.1	24.7	245.4	25-Feb-20	476
Russia	0.04	5.9	623.7	30-Jan-20	469
San Marino	100.2	822.3	1727	26-Feb-20	3013
Serbia	0.7	30.5	123.2	05-Mar-20	494
Singapore	0.1	27.7	1111	22-Jan-20	2462
Slovakia	0.04	12.5	360.5	05-Mar-20	1178
Slovenia	1.9	52.5	1475.2	03-Mar-20	1834
South Africa	0.02	2.9	98	04-Mar-20	428
South Korea	0.4	20.3	931	19-Jan-20	2043
Spain	31.1	313.7	759.3	30-Jan-20	2390
Sri Lanka	0.03	0.9	15.2	26-Jan-20	153
Sweden	6.8	83.4	541.6	30-Jan-20	5711
Switzerland	9.9	263.3	1986.7	24-Feb-20	9836
Thailand	0.04	3.4	103	12-Jan-20	222
Togo	0.04	0.8	21.1	05-Mar-20	39
Trinidad and Tobago	0.6	7.6	62.7	11-Mar-20	1064
Tunisia	0.2	5.3	70	01-Mar-20	257
Turkey	0.9	40.4	264.3	09-Mar-20	469
Ukraine	0.1	3.8	16.5	02-Mar-20	141
United Arab Emirates	0.1	26.9	5451.7	28-Jan-20	1323
United Kingdom	9.1	81.4	392.9	30-Jan-20	3958
United States	3.9	122.1	636.7	20-Jan-20	9870
Uruguay	0.2	12.2	164.9	12-Mar-20	1379
Zambia	0.005	0.2	3.4	17-Mar-20	57
Zimbabwe	0.01	0.07	2.5	19-Mar-20	94

# Table 4. Country level, multivariate linear regression of factors associated with COVID-19 mortality rate per 100 000 inhabitants. Sensitivity analysis limited to countries with epidemics starting prior to 15 March 2020.

	Coef. (95% Confidence Interval)	P-Value
N	98	
Tests/capita	-0.036 (-0.0050.002)	<0.001
Cases/capita	0.093 (0.081- 0.104)	<0.001
Age of Epidemic	-0.107 (-0.2000.014)	0.024
Health Expenditure	-0.0010 (-0.00170.0002)	0.012
Region		
Europe	Ref	
Africa	-0.163 (-4.992-4.664)	0.946
Americas	0.046 (-3.249-3.149)	0.977
Eastern Mediterranean	0.906 (-3.0188-4.830)	0.648
South East Asia	-3.037(-8.874-2.799)	0.304
Western Pacific	0.240 (-5.091-4.651)	0.922

#### References

231

- 232 1. Rubino S, Kelvin N, Bermejo-Martin JF, Kelvin D. As COVID-19 cases, deaths and
- fatality rates surge in Italy, underlying causes require investigation. The Journal of Infection
- 234 in Developing Countries. 2020;14(03):265-7.
- 235 2. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-
- based mitigation measures influence the course of the COVID-19 epidemic? The Lancet.
- 237 2020;395(10228):931-4.
- 238 3. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality
- 239 Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries.
- 240 2020;14(2):125-8. Epub 2020/03/09. doi: 10.3855/jidc.12600. PubMed PMID: 32146445.
- 4. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating
- 242 clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature
- 243 Medicine. 2020:1-5.
- 244 5. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 -
- 245 Studies Needed. N Engl J Med. 2020;382(13):1194-6. Epub 2020/02/20. doi:
- 246 10.1056/NEJMp2002125. PubMed PMID: 32074416.
- 247 6. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al.
- 248 Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality
- and healthcare demand. 2020.
- 250 7. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
- proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess
- 252 cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10). Epub 2020/03/19. doi:
- 253 10.2807/1560-7917.ES.2020.25.10.2000180. PubMed PMID: 32183930; PubMed Central
- 254 PMCID: PMCPMC7078829.
- 255 8. Zhang Z, Yao W, Wang Y, Long C, Fu X. Wuhan and Hubei COVID-19 mortality
- analysis reveals the critical role of timely supply of medical resources. J Infect. 2020. Epub
- 257 2020/03/27. doi: 10.1016/j.jinf.2020.03.018. PubMed PMID: 32209384.
- 258 9. Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, et al.
- 259 Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using
- age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020.
- 261 Eurosurveillance. 2020;25(12):2000256.